12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Company News  |  Other News

MagForce cancer news

MagForce will reduce its headcount by 15 (56%) to 12 to focus on commercialization of its NanoTherm therapy. The company said it will focus its financial resources on a postmarketing trial of the therapy in glioblastoma, which is slated...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >